Recent Company News

• 03:01 PM ET Feb 10, 2026
  

  FDA grants orphan drug designation to zenocutuzumab for the treatment of cholangiocarcinoma (DKK 1938.00, 0.00)

• 08:56 AM ET Jan 28, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:16 PM ET Jan 28, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 11:59 PM ET Jan 30, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 10:37 AM ET Jan 30, 2026
  

  $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

• 03:52 PM ET Jan 27, 2026
  

  Johnson & Johnson confirms DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible ($224.55, +3.05)